Immuron Limited
Research Immuron Limited (ANW) on Bullrun: market cap EUR 4.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANW
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 4.04M
- Financial periodFY2025
- RevenueAUD 7.29M
- Revenue growth48.6%
- Net income-AUD 5.22M
- Free cash flow-AUD 6.14M
- Gross margin65.4%
Valuation Snapshot
latest market cap is EUR 4.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 7.29M | -AUD 5.22M | -AUD 6.14M | 65.4% | -0.02 | AUD 2.83M | AUD 71.86K | AUD 8.07M |
| FY2024 | AUD 4.90M | -AUD 6.94M | -AUD 5.88M | 68.1% | -0.03 | AUD 11.66M | AUD 132.94K | AUD 12.71M |
| FY2023 | AUD 1.80M | -AUD 3.79M | -AUD 2.60M | 72.5% | -0.02 | AUD 17.16M | AUD 189.09K | AUD 19.62M |
| FY2022 | AUD 765.19K | -AUD 2.85M | -AUD 3.16M | 68.4% | -0.01 | AUD 22.11M | AUD 209.79K | AUD 23.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 4.04M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immuron Limited's market cap?
Immuron Limited's market capitalization is EUR 4.04M.
What does Immuron Limited do?
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.